📊 AIM Key Takeaways
Is AIM ImmunoTech Inc. (AIM) a Good Investment?
AIM ImmunoTech is in critical financial distress with negative stockholders' equity of -$6.1M, indicating liabilities exceed assets by a substantial margin. The company generated only $67K in revenue against $9.8M in net losses, with operating cash flow of -$9.0M, demonstrating severe operational dysfunction and inability to generate sustainable revenue. With 9 months of cash burn at current rates remaining before depletion, the company faces imminent solvency risk unless it secures immediate capital or achieves dramatic operational turnaround.
AIM ImmunoTech’s fundamentals are extremely weak: revenue is negligible at $67K while operating and free cash flow losses are near $9M, producing deeply negative margins that indicate the business is not commercially self-sustaining. The balance sheet is also distressed, with negative equity, liabilities exceeding assets, and sub-1.0 liquidity ratios, which raises significant going-concern and financing risk. While cash on hand provides some short-term flexibility, the overall financial profile points to very poor growth quality and high dependence on external capital.
Why Buy AIM ImmunoTech Inc. Stock? AIM Key Strengths
- Maintains $2.3M in cash reserves providing near-term liquidity cushion
- Recent insider activity (5 Form 4 filings in 90 days) suggests management engagement
- Operates in biologics sector with potential for breakthrough therapies if pipeline succeeds
- Cash and equivalents of $2.35M provide limited near-term operating flexibility
- Capital expenditure requirements are minimal, which reduces fixed reinvestment pressure
- EPS loss improved year over year, indicating some reduction in per-share loss pressure
AIM Stock Risks: AIM ImmunoTech Inc. Investment Risks
- Negative stockholders' equity of -$6.1M indicates technical insolvency and shareholder dilution risk
- Revenue of $67K against $9.8M net loss indicates fundamentally broken business model
- Operating cash burn of $9.0M annually will deplete cash reserves in approximately 3 months at current burn rate
- Current ratio of 0.64x indicates inability to meet short-term obligations
- Extreme negative margins (-13,003% operating margin) demonstrate complete lack of operational profitability
- Revenue base is immaterial relative to operating costs, resulting in extreme negative operating and net margins
- Negative stockholders equity and liabilities above assets indicate a severely weakened balance sheet
- Operating cash flow and free cash flow are deeply negative, implying continued dependence on outside financing
Key Metrics to Watch
- Cash balance and runway until capital raise or insolvency
- Monthly revenue growth trajectory and pipeline advancement
- Operating cash burn rate and path to cash flow breakeven
- Stockholders' equity recovery through capital injection or operational profitability
- Quarterly cash burn relative to cash balance
- Any material increase in revenue versus operating expense base
AIM ImmunoTech Inc. (AIM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
AIM Profit Margin, ROE & Profitability Analysis
AIM vs Healthcare Sector: How AIM ImmunoTech Inc. Compares
How AIM ImmunoTech Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is AIM ImmunoTech Inc. Stock Overvalued? AIM Valuation Analysis 2026
Based on fundamental analysis, AIM ImmunoTech Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
AIM ImmunoTech Inc. Balance Sheet: AIM Debt, Cash & Liquidity
AIM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: AIM ImmunoTech Inc.'s revenue has shown modest growth of 4% over the 5-year period. The most recent EPS of $-30.92 indicates the company is currently unprofitable.
AIM Revenue Growth, EPS Growth & YoY Performance
AIM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $26.0K | -$1.8M | $1.57 |
| Q2 2025 | $25.0K | -$1.8M | $-3.00 |
| Q1 2025 | $16.0K | -$3.7M | $-0.05 |
| Q3 2024 | $35.0K | -$3.7M | $-0.06 |
| Q2 2024 | $42.0K | -$1.8M | $-0.03 |
| Q1 2024 | $40.0K | -$3.7M | $-0.08 |
| Q3 2023 | $21.0K | -$6.4M | $-0.13 |
| Q2 2023 | $30.0K | -$4.9M | $-0.10 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AIM ImmunoTech Inc. Dividends, Buybacks & Capital Allocation
AIM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for AIM ImmunoTech Inc. (CIK: 0000946644)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AIM
What is the AI rating for AIM?
AIM ImmunoTech Inc. (AIM) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AIM's key strengths?
Claude: Maintains $2.3M in cash reserves providing near-term liquidity cushion. Recent insider activity (5 Form 4 filings in 90 days) suggests management engagement. ChatGPT: Cash and equivalents of $2.35M provide limited near-term operating flexibility. Capital expenditure requirements are minimal, which reduces fixed reinvestment pressure.
What are the risks of investing in AIM?
Claude: Negative stockholders' equity of -$6.1M indicates technical insolvency and shareholder dilution risk. Revenue of $67K against $9.8M net loss indicates fundamentally broken business model. ChatGPT: Revenue base is immaterial relative to operating costs, resulting in extreme negative operating and net margins. Negative stockholders equity and liabilities above assets indicate a severely weakened balance sheet.
What is AIM's revenue and growth?
AIM ImmunoTech Inc. reported revenue of $67.0K.
Does AIM pay dividends?
AIM ImmunoTech Inc. does not currently pay dividends.
Where can I find AIM SEC filings?
Official SEC filings for AIM ImmunoTech Inc. (CIK: 0000946644) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AIM's EPS?
AIM ImmunoTech Inc. has a diluted EPS of $-8.18.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AIM a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, AIM ImmunoTech Inc. has a STRONG SELL rating with 96% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is AIM stock overvalued or undervalued?
Valuation metrics for AIM: ROE of N/A (sector avg: 15%), net margin of -14,601.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy AIM stock in 2026?
Our dual AI analysis gives AIM ImmunoTech Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AIM's free cash flow?
AIM ImmunoTech Inc.'s operating cash flow is $-9.0M, with capital expenditures of $18.0K. FCF margin is -13,416.4%.
How does AIM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -14,601.5% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.64 (avg: 2).